Zelapar

Treatment for Parkinson's Disease

Valeant Pharmaceuticals Receives Approvable Letter from FDA Regarding Zelapar

COSTA MESA, Calif., October 4, 2005 - Valeant Pharmaceuticals International (NYSE:VRX) today announced that the company received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zelapar (selegiline hydrochloride). The approvable letter requests additional clarification on specific issues previously addressed by Valeant. Valeant plans to meet with the FDA, promptly as they have requested, to discuss and resolve these matters.

Source: Valeant Pharmaceuticals

Click here for more information on Zelapar

Posted: October 2005

Related Articles

Zelapar (selegiline hydrochloride) FDA Approval History

View comments

Hide
(web5)